- Home
- FMAO vs XERS Comparison
FMAO vs XERS Comparison
Compare FMAO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- XERS
- Stock Information
- Founded
- FMAO 1897
- XERS 2005
- Country
- FMAO United States
- XERS United States
- Employees
- FMAO N/A
- XERS N/A
- Industry
- FMAO Savings Institutions
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- XERS Health Care
- Exchange
- FMAO Nasdaq
- XERS Nasdaq
- Market Cap
- FMAO 377.5M
- XERS 444.0M
- IPO Year
- FMAO N/A
- XERS 2018
- Fundamental
- Price
- FMAO $32.00
- XERS $3.05
- Analyst Decision
- FMAO Hold
- XERS Buy
- Analyst Count
- FMAO 2
- XERS 3
- Target Price
- FMAO $26.00
- XERS $4.87
- AVG Volume (30 Days)
- FMAO 26.6K
- XERS 1.9M
- Earning Date
- FMAO 10-30-2024
- XERS 11-08-2024
- Dividend Yield
- FMAO 2.80%
- XERS N/A
- EPS Growth
- FMAO N/A
- XERS N/A
- EPS
- FMAO 1.69
- XERS N/A
- Revenue
- FMAO $98,003,000.00
- XERS $187,361,000.00
- Revenue This Year
- FMAO N/A
- XERS $20.35
- Revenue Next Year
- FMAO $7.93
- XERS $16.14
- P/E Ratio
- FMAO $18.71
- XERS N/A
- Revenue Growth
- FMAO N/A
- XERS 22.72
- 52 Week Low
- FMAO $18.58
- XERS $1.69
- 52 Week High
- FMAO $33.75
- XERS $3.64
- Technical
- Relative Strength Index (RSI)
- FMAO 62.48
- XERS 49.79
- Support Level
- FMAO $31.24
- XERS $2.82
- Resistance Level
- FMAO $32.74
- XERS $3.33
- Average True Range (ATR)
- FMAO 1.07
- XERS 0.18
- MACD
- FMAO 0.01
- XERS -0.04
- Stochastic Oscillator
- FMAO 69.54
- XERS 33.54
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company for Farmers & Merchants Bank of Central California. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.